As for ICI+ chemotherapy, patients with EGFR20ins mutations can achieve longer PFS, while the limited efficacy in HER2-20ins may be due to differences in the tumor microenvironment of the two mutations. This evidence concerns the gene ERBB2 and neoplasm.